Breaking News Instant updates and real-time market news.

GNFT

Genfit

$16.62

-0.29 (-1.72%)

09:39
09/11/19
09/11
09:39
09/11/19
09:39

Genfit risk/reward 'extremely compelling' after selloff, says B. Riley FBR

B. Riley FBR analyst Mayank Mamtani finds Genfit's risk/reward profile "extremely compelling" at current levels following the recent selloff in the shares. The analyst expects a "sentiment turnaround" ahead of the company's Phase III Resolve-It trial results in Q1 of 2020. Genfit's lead program elafibranor offers one of the "very few" development programs currently in Phase III for large patient population non-alcoholic steatohepatitis, which is "also scientifically and clinically de-risked in a meaningful way," Mamtani tells investors in a research note. He reiterates a Buy rating on Genfit shares with a $52 price target.

GNFT Genfit
$16.62

-0.29 (-1.72%)

05/14/19
HCWC
05/14/19
NO CHANGE
HCWC
H.C. Wainwright affirms Buy on Genfit after positive recommendation from DSMB
H.C. Wainwright analyst Ed Arce affirmed a Buy rating and $72 price target on Genfit after the company announced that the the Data Safety Monitoring Board, or DSMB, of the Phase 3 RESOLVE-IT trial of elafibranor for the treatment of NASH, or nonalcoholic steatohepatitis, had "rendered a positive recommendation for the trial's continuation without any changes. This 36-month safety review is the sixth planned review by the DSMB, and revealed no safety issues with elafibranor." The analyst estimates elafibranor's probability of success at 75% for NASH and 60% for PBC, and utilize a 11.5% discount rate, which he believes is "appropriate for a small-cap development stage biotech."
06/11/19
PIPR
06/11/19
NO CHANGE
Target $8
PIPR
Overweight
Piper cuts CymaBay price target to $8 on 'worst case' results for NASH trial
Piper Jaffray analyst Tyler Van Buren said he did not anticipate that placebo would perform better than seladelpar in CymaBay Therapeutics' (CBAY) Phase 2b study of the drug for the treatment of nonalcoholic steatohepatitis. Calling the NASH trial results a "worst case scenario," Van Buren sees significant risk to the final 52-week data read-out and removed all expectations in NASH from his model. He said the data make seladelpar seem similar to Genfit's (GNFT) elafibranor, though seladelpar has not yet shown improvements in good cholesterol, glucose homeostatis, or insulin resistance. While Van Buren cut his price target on CymaBay shares to $8 from $30 based on the trial results, he keeps an Overweight rating on the shares given the sharp pullback this morning and the support he sees from the company's remaining cash and residual opportunity.
06/25/19
STFL
06/25/19
INITIATION
Target $126
STFL
Hold
Madrigal Pharmaceuticals initiated with a Hold at Stifel
Stifel analyst Derek Archila initiated Madrigal Pharmaceuticals (MDGL) with a Hold rating and $126 price target, stating that he is positively biased heading into Phase 3 amid emerging evidence that point to the possibility resmetirom could demonstrate a benefit on fibrosis over time. However, he thinks the stock could be volatile around updates from competitors such as Viking Therapeutics (VKTX) and Genfit (GNFT) and sees few catalysts specific to Madrigal to drive shares up in the next 12-18 months, Archila tells investors.
06/25/19
STFL
06/25/19
INITIATION
STFL
Hold
Genfit initiated with a Hold at Stifel
Stifel analyst Derek Archila started Genfit with a Hold rating and EUR21 price target, telling investors that he finds it hard to have conviction about a positive read out for the Phase 3 RESOLVE-IT study of elafibranor in on-alcoholic steatohepatitis based on the drug's current data. He questions the drug's commercial viability if it only demonstrates a marginal benefit on NASH resolution, Archila added in his initiation note.

TODAY'S FREE FLY STORIES

01:50
09/19/19
09/19
01:50
09/19/19
01:50
General news
Asian Market Wrap »

Asian Market Wrap: Asian…

01:40
09/19/19
09/19
01:40
09/19/19
01:40
General news
Norges Bank decision could go either way. »

Norges Bank decision…

01:20
09/19/19
09/19
01:20
09/19/19
01:20
General news
U.S. initial claims preview »

U.S. initial claims…

01:20
09/19/19
09/19
01:20
09/19/19
01:20
General news
U.S. Philly Fed preview »

U.S. Philly Fed preview:…

01:20
09/19/19
09/19
01:20
09/19/19
01:20
General news
U.S. existing home sales preview »

U.S. existing home sales…

01:15
09/19/19
09/19
01:15
09/19/19
01:15
General news
BoJ left policy on hold »

BoJ left policy on hold…

AKAM

Akamai

$90.95

-0.13 (-0.14%)

21:13
09/18/19
09/18
21:13
09/18/19
21:13
Downgrade
Akamai rating change at KeyBanc »

Akamai downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

DB

Deutsche Bank

$8.06

-0.125 (-1.53%)

20:32
09/18/19
09/18
20:32
09/18/19
20:32
Hot Stocks
Deutsche Bank lowers prime lending rate to 5.00% from 5.25% »

Deutsche Bank announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRVB

Provention Bio

$9.70

0.33 (3.52%)

20:31
09/18/19
09/18
20:31
09/18/19
20:31
Syndicate
Provention Bio 5M share Spot Secondary priced at $8.00 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 19

    Sep

DRI

Darden

$127.40

1.31 (1.04%)

20:25
09/18/19
09/18
20:25
09/18/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 19

    Sep

XGN

Exagen

$0.00

(0.00%)

19:48
09/18/19
09/18
19:48
09/18/19
19:48
Syndicate
Exagen 3.6M share IPO priced at $14.00 »

The deal priced at low…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

PING

Ping Identity

$0.00

(0.00%)

19:35
09/18/19
09/18
19:35
09/18/19
19:35
Syndicate
Ping Identity 12.5M share IPO priced at $15.00 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

CBS

CBS

$43.38

0.08 (0.18%)

, T

AT&T

$36.77

-0.39 (-1.05%)

19:04
09/18/19
09/18
19:04
09/18/19
19:04
Periodicals
Viacom, CBS, WarnerMedia pull e-cigarette ads from networks, CNBC says »

CBS (CBS),…

CBS

CBS

$43.38

0.08 (0.18%)

T

AT&T

$36.77

-0.39 (-1.05%)

VIA

Viacom

$27.94

-0.06 (-0.21%)

VIAB

Viacom

$25.77

0.02 (0.08%)

BTI

British American Tobacco

$36.90

0.06 (0.16%)

MO

Altria Group

$40.84

-0.47 (-1.14%)

PM

Philip Morris

$71.58

-0.4 (-0.56%)

IMBBY

Imperial Brands

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 12

    Nov

CRON

Cronos Group

$10.96

-0.205 (-1.84%)

18:57
09/18/19
09/18
18:57
09/18/19
18:57
Hot Stocks
Cronos Group CEO: We focus on supply and the consumer »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLHR

Herman Miller

$44.48

-0.02 (-0.04%)

, SVRA

Savara

$2.49

-0.14 (-5.32%)

18:46
09/18/19
09/18
18:46
09/18/19
18:46
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

MLHR

Herman Miller

$44.48

-0.02 (-0.04%)

SVRA

Savara

$2.49

-0.14 (-5.32%)

CBPO

China Biologic

$103.19

0.37 (0.36%)

NCR

NCR Corp.

$33.62

0.77 (2.34%)

MSFT

Microsoft

$138.53

1.13 (0.82%)

TNDM

TNDM

X

U.S. Steel

$12.45

-0.51 (-3.94%)

PRVB

Provention Bio

$9.70

0.33 (3.52%)

PAA

Plains All American

$21.87

-0.315 (-1.42%)

COST

Costco

$292.47

0.96 (0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 19

    Sep

  • 23

    Sep

  • 01

    Oct

  • 02

    Oct

  • 03

    Oct

  • 21

    Oct

  • 22

    Oct

  • 27

    Oct

  • 05

    Nov

  • 19

    Sep

  • 19

    Sep

  • 19

    Sep

TECD

Tech Data

$103.32

-0.59 (-0.57%)

18:41
09/18/19
09/18
18:41
09/18/19
18:41
Hot Stocks
Tech Data CEO: We are confident in our company and where we are going »

Tech Data CEO Richard…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$36.77

-0.39 (-1.05%)

, DISH

Dish

$35.58

0.3 (0.85%)

18:34
09/18/19
09/18
18:34
09/18/19
18:34
Periodicals
AT&T, Dish not in discussions over DirecTV deal, Reuters reports »

AT&T (T) and Dish…

T

AT&T

$36.77

-0.39 (-1.05%)

DISH

Dish

$35.58

0.3 (0.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 23

    Oct

AGCO

Agco

$76.04

-0.16 (-0.21%)

18:30
09/18/19
09/18
18:30
09/18/19
18:30
Hot Stocks
Agco CEO: We are on schedule in the U.S. »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBR

Petrobras

$14.63

-0.31 (-2.08%)

18:22
09/18/19
09/18
18:22
09/18/19
18:22
Periodicals
Petrobras raises gasoline, diesel prices in wake of Saudi attacks, Reuters says »

Petrobras has boosted the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$123.69

-0.28 (-0.23%)

18:01
09/18/19
09/18
18:01
09/18/19
18:01
Hot Stocks
Celanese increases Vinyl Acetate Monomer price in EMEA by EUR50/MT »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STI

SunTrust

$68.57

0.48 (0.70%)

18:00
09/18/19
09/18
18:00
09/18/19
18:00
Hot Stocks
SunTrust lowers prime lending rate to 5% from 5.25% »

Following the Federal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WBS

Webster Financial

$48.84

0.43 (0.89%)

17:53
09/18/19
09/18
17:53
09/18/19
17:53
Hot Stocks
Webster Financial lowers prime lending rate to 5.0% from 5.25% 

Effective September 19.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 13

    Nov

HSBC

HSBC

$38.19

-0.1 (-0.26%)

17:52
09/18/19
09/18
17:52
09/18/19
17:52
Hot Stocks
HSBC decreases prime lending rate to 5% from 5.25% »

HSBC Bank USA and its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

HES

Hess Corp.

$66.91

-0.92 (-1.36%)

17:50
09/18/19
09/18
17:50
09/18/19
17:50
Hot Stocks
Hess Corp. COO sells 17,750 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 02

    Oct

CSCO

Cisco

$49.32

-0.1 (-0.20%)

, DDOG

Datadog

$0.00

(0.00%)

17:46
09/18/19
09/18
17:46
09/18/19
17:46
Periodicals
Cisco approached Datadog with $7B+ takeover bid, Bloomberg says »

Cisco (CSCO) approached…

CSCO

Cisco

$49.32

-0.1 (-0.20%)

DDOG

Datadog

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Oct

  • 13

    Nov

  • 19

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.